The press releases are available in Swedish when no translation exists.
Chordate Medical Holding AB (publ) ("Chordate" or "the Company") hereby announces that the Board has today decided to bring forward the company's report for Q3 2021 to give owners and stakeholders in the outstanding warrant TO7 the opportunity to view the quarterly report before trading in the option ends October 27, 2021, and before October 29, 2021, which is the last day for redemption of TO7. The report for the period July-September 2021 will be published on October 25 2021 instead of November 19 as previously communicated.
The company's financial calendar has been updated and can be found at https://www.chordate.com/en/investor-relations/financial-calendar/
This disclosure was submitted for publication, through the contact person below, on September 23rd, 2021, at 16:00 pm CET.
For more information, please contact:
Anders WeilandtManaging DirectorCell: +46 733-874277, e-mail: email@example.com
About Chordate Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM - SME (ticker: CMH). Read more athttps://www.chordate.com/en/
Press releases and reports via E-mail.
We are a Swedish medical technology company listed on NGM Nordic SME.
Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.